Nov. 24, 2015
Uni-Bio Science Group Limited announced that it will acquire the exclusive global rights to manufacture and commercialise mitiglinide, a new oral antidiabetic agent, from Jiangsu Hansoh Pharmaceutical Co. Ltd.
Mitiglinide is a new, oral antidiabetic agent which belongs to the glinides class of blood glucose lowering compounds. It is known to improve postprandial hyperglycemia in patients with Type 2 diabetes and has received new drug approval as a first and/or second line of treatment for the disease from the China Food and Drug Administration. It is the market leader of the glinides class of Type 2 diabetes treatments in Japan, generating $140 million in revenue in 2014.
Hansoh has developed its own version of mitiglinide, which is currently being marketed and sold in China.
Under the terms of the agreement, Uni-Bio will manufacture the drug in its CGMP-certified plant in Beijing and market it in China. In other markets Uni-Bio will seek distribution partners.